Merck posts press release on once-weekly oral HIV regimen trial results
MRK•Phase 3 HIV regimen data
- Merck posted a press release on Phase 3 ISLEND-1 and ISLEND-2 data for once-weekly oral islatravir/lenacapavir in virologically suppressed adults with HIV.
- The week 48 endpoint was met, showing noninferior viral suppression versus BIKTARVY in ISLEND-1, and versus daily standard-of-care regimens in ISLEND-2.
- Results are slated for late-breaking presentation at AIDS 2026 on July 29, forming the basis for regulatory filings.
Related News
Developed market debt to hit record $75.8 trillion as shocks and spending pressures mount, Fitch says
TLT•
Okta wins DoD impact level 5 provisional authorization for US Military cloud service
OKTA•
